2024 Q4 Form 10-Q Financial Statement

#000095017024125437 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.02M
YoY Change 4.93%
% of Gross Profit
Research & Development $60.63M
YoY Change 45.74%
% of Gross Profit
Depreciation & Amortization $156.0K
YoY Change -9.3%
% of Gross Profit
Operating Expenses $76.65M
YoY Change 34.79%
Operating Profit -$76.65M
YoY Change 34.79%
Interest Expense $4.209M
YoY Change 9.67%
% of Operating Profit
Other Income/Expense, Net $4.152M
YoY Change 8.21%
Pretax Income -$72.49M
YoY Change 36.71%
Income Tax $53.00K
% Of Pretax Income
Net Earnings -$72.55M
YoY Change 36.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45
Diluted Earnings Per Share -$0.45
COMMON SHARES
Basic Shares Outstanding 161.6M 160.0M
Diluted Shares Outstanding 159.6M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $341.3M
YoY Change -33.02%
Cash & Equivalents $275.7M
Short-Term Investments $65.59M
Other Short-Term Assets $7.301M
YoY Change -52.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $348.6M
YoY Change -33.69%
LONG-TERM ASSETS
Property, Plant & Equipment $1.297M
YoY Change -32.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $3.929M
YoY Change -79.34%
TOTAL ASSETS
Total Short-Term Assets $348.6M
Total Long-Term Assets $3.929M
Total Assets $352.5M
YoY Change -35.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.107M
YoY Change 173.98%
Accrued Expenses $22.76M
YoY Change -2.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.74M
YoY Change 9.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $55.00K
YoY Change -98.12%
Total Long-Term Liabilities $55.00K
YoY Change -98.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.74M
Total Long-Term Liabilities $55.00K
Total Liabilities $31.80M
YoY Change -0.8%
SHAREHOLDERS EQUITY
Retained Earnings -$888.4M
YoY Change 49.39%
Common Stock $1.209B
YoY Change 9.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $320.7M
YoY Change
Total Liabilities & Shareholders Equity $352.5M
YoY Change -35.28%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$72.55M
YoY Change 36.81%
Depreciation, Depletion And Amortization $156.0K
YoY Change -9.3%
Cash From Operating Activities -$33.48M
YoY Change -29.92%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $157.0M
YoY Change 558.15%
Cash From Investing Activities $157.0M
YoY Change 559.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.531M
YoY Change -99.34%
NET CHANGE
Cash From Operating Activities -33.48M
Cash From Investing Activities 157.0M
Cash From Financing Activities 1.531M
Net Change In Cash 125.0M
YoY Change -39.9%
FREE CASH FLOW
Cash From Operating Activities -$33.48M
Capital Expenditures $0.00
Free Cash Flow -$33.48M
YoY Change -29.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001885522
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1274
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41802
dei Entity Registrant Name
EntityRegistrantName
NEUMORA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4367680
dei Entity Address Address Line1
EntityAddressAddressLine1
490 Arsenal Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
760-0900
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NMRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161561064
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275714000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
374038000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1213000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
65593000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
79944000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6088000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24297000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
348608000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
478279000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9845000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1297000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1790000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2632000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5068000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2024Q3 us-gaap Assets
Assets
352537000
CY2023Q4 us-gaap Assets
Assets
496195000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6107000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
337000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22758000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21257000
CY2024Q3 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
133000
CY2023Q4 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
139000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2745000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3378000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31743000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25111000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1853000
CY2024Q3 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
55000
CY2023Q4 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
155000
CY2024Q3 us-gaap Liabilities
Liabilities
31798000
CY2023Q4 us-gaap Liabilities
Liabilities
27119000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1209020000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1172570000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
105000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-76000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-888402000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-703434000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
320739000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
469076000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352537000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
496195000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60630000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41601000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155015000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103855000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16016000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15263000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45527000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34239000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
76646000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
56864000
us-gaap Operating Expenses
OperatingExpenses
200542000
us-gaap Operating Expenses
OperatingExpenses
138094000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-76646000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-56864000
us-gaap Operating Income Loss
OperatingIncomeLoss
-200542000
us-gaap Operating Income Loss
OperatingIncomeLoss
-138094000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4209000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3838000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15845000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10965000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-57000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-93000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4152000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3837000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15752000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10899000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72494000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53027000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-184790000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-127195000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
53000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
178000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72547000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-53027000
us-gaap Net Income Loss
NetIncomeLoss
-184968000
us-gaap Net Income Loss
NetIncomeLoss
-127195000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
292000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
137000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
181000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
463000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72255000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52890000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-184787000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-126732000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159576000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159576000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46691000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46691000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
158837000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158837000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35428000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35428000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
469076000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1845000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
41000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-72000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7373000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-53721000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
424542000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2654000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
34000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-39000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12768000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-58700000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
381259000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1756000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
33000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
292000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9946000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72547000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
320739000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-446850000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
602000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1282000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
476000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2195000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35625000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-477920000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
404000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
125000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-150000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2543000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38543000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-513541000
CY2023Q3 nmra Conversion Of Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Value
ConversionOfConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingValue
843687000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
226618000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1511000
CY2023Q3 nmra Sale And Issuance Of Common Stock
SaleAndIssuanceOfCommonStock
810000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
47000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
137000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6451000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-53027000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
512693000
us-gaap Profit Loss
ProfitLoss
-184968000
us-gaap Profit Loss
ProfitLoss
-127195000
us-gaap Share Based Compensation
ShareBasedCompensation
30087000
us-gaap Share Based Compensation
ShareBasedCompensation
11189000
nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
2436000
nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
2469000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
474000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
502000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
4638000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
3068000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-54000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15306000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3274000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5770000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1331000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5401000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8646000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2485000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2490000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132596000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111836000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
205324000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
89000000
nmra Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
234341000
nmra Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
139783000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
775000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28242000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50710000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
232565000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6255000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2517000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
810000
nmra Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
491000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
225000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2984000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6030000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
232417000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-98324000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
171291000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
375251000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242206000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
276927000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
413497000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275714000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
412284000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
1213000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1213000
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
276927000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
413497000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
473000
nmra Offering Costs Connection With At The Market Offering Included In Accrued Liabilities
OfferingCostsConnectionWithAtTheMarketOfferingIncludedInAccruedLiabilities
321000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
843687000
nmra Offering Costs Related To Initial Public Offering Included In Accounts Payable And Accrued Liabilities
OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities
2963000
CY2024Q3 nmra Number Of Clinical And Preclinical Neuroscience Programs
NumberOfClinicalAndPreclinicalNeurosciencePrograms
7
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
7.8463-for-1
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the fair value of the Company’s common stock,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company’s estimates.</span></p>
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
332276000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
114000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
9000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
332381000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
452119000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
26000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
102000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
452043000
CY2024Q3 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
1
CY2024Q3 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
11606000
CY2023Q4 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
4705000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8844000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10011000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1916000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
392000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
750000
CY2024Q3 nmra Accrued Research And Development Services Due To Related Party
AccruedResearchAndDevelopmentServicesDueToRelatedParty
0
CY2023Q4 nmra Accrued Research And Development Services Due To Related Party
AccruedResearchAndDevelopmentServicesDueToRelatedParty
3100000
CY2023Q4 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
5004000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22758000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21257000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
35822000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9946000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6451000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30087000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11189000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-72547000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-53027000
us-gaap Net Income Loss
NetIncomeLoss
-184968000
us-gaap Net Income Loss
NetIncomeLoss
-127195000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
159576000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
159576000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46691000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46691000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158837000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
158837000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35428000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35428000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16555000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16488000

Files In Submission

Name View Source Status
0000950170-24-125437-index-headers.html Edgar Link pending
0000950170-24-125437-index.html Edgar Link pending
0000950170-24-125437.txt Edgar Link pending
0000950170-24-125437-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img235852261_0.jpg Edgar Link pending
img235852261_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nmra-20240930.htm Edgar Link pending
nmra-20240930.xsd Edgar Link pending
nmra-ex31_1.htm Edgar Link pending
nmra-ex31_2.htm Edgar Link pending
nmra-ex32_1.htm Edgar Link pending
nmra-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
nmra-20240930_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable